Compare · EGRX vs LLY
EGRX vs LLY
Side-by-side comparison of Eagle Pharmaceuticals Inc. (EGRX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EGRX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.35T.
- LLY has been more active in the news (31 items in the past 4 weeks vs 1 for EGRX).
- LLY has more recent analyst coverage (25 ratings vs 2 for EGRX).
- Company
- Eagle Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- -
- $1.35T
- 1M return
- -
- +14.06%
- 1Y return
- -
- +40.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 1
- 31
- Recent ratings
- 2
- 25
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest EGRX
- Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
- Glancy Prongay Wolke & Rotter LLP, as Lead Counsel, Obtained $9.5 Million Settlement for Eagle Pharmaceuticals, Inc. Investors
- Eagle Pharmaceuticals Announces Divestiture of Barhemsys
- Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
- Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders
- Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
- Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
- Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
- Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
- Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
Latest LLY
- Stocks Carry Weekly Gains Into a Wall of Chart Resistance as Volatility Cools
- Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
- Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
- Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
- EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)
- Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss